ROCHE HOLDINGS AG News

Roche's Genentech Granted Priority Review By FDA For Inavolisib, An Investigational Oral Therapy, In Combination With Palbociclib (Ibrance) And Fulvestrant

– Priority Review recognizes the best-in-class potential of the inavolisib-based regimen for patients in urgent need of new treatment options –– Additional analyses of INAVO120 will be presented in an

BenzingaMay 29 01:08 ET

Reported Earlier, Roche And Hitachi High-Tech Extend 46-Year Partnership For Diagnostic Testing Advances

Renewed partnership combines best in class engineering capabilities with cutting edge science to accelerate the availability of new solutions for customers and patients worldwideUpcoming launches of t

BenzingaMay 28 03:27 ET

Roche and Hitachi High-Tech Extend Their 46-year Partnership, Paving the Way for Further Breakthroughs in Diagnostic Testing

Yahoo FinanceMay 27 01:00 ET

FDA Grants Breakthrough Therapy Designation to Roche's Inavolisib for Advanced Hormone Receptor-positive, HER2-negative Breast Cancer With a PIK3CA Mutation

Yahoo FinanceMay 21 01:00 ET

Viking Falls After Roche's Obesity Drug Data

Seeking AlphaMay 16 13:37 ET

Roche Obesity Therapy Leads to ~19% Weight Loss in Phase 1 Trial

Roche (OTCQX:RHHBY) announced Thursday that its gut-hormone-mimicking obesity therapy, CT-388, caused 18.8% of weight loss on average over 24 weeks compared to placebo in a Phase 1 trial for healthy adults with obesity.

Seeking AlphaMay 16 06:48 ET

[Ad Hoc Announcement Pursuant to Art. 53 LR] Roche Reports Positive Phase I Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People With Obesity

Yahoo FinanceMay 16 01:00 ET

Roche Announces FDA Approval of One of the First HPV Self-collection Solutions in the U.S., Expanding Access and Screening Options to Help Eliminate Cervical Cancer

Yahoo FinanceMay 15 01:00 ET

Sarepta Upgraded at Oppenheimer on Potential Elevidys Label Expansion

Seeking AlphaMay 14 09:00 ET

TG Therapeutics Wins VA Contract for Briumvi

Seeking AlphaApr 18 13:15 ET

Roche's Multiple Sclerosis Injection Controls Relapses, Brain Lesions in Late-stage Trial

Roche (ROG.SW, RO.SW) on Wednesday said the subcutaneous formula of Ocrevus showed nearly complete suppression of clinical relapses and brain lesions in multiple sclerosis patients at 48 weeks, citing updated late-stage data.

MT NewswiresApr 17 05:47 ET

[Ad Hoc Announcement Pursuant to Art. 53 LR] Roche's Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma in Phase III STARGLO Study

Yahoo FinanceApr 15 01:00 ET

Adaptimmune Slips as Roche Strategic Collaboration Ends

Seeking AlphaApr 12 08:53 ET

Express News | Roche Obtains CE Mark For First Companion Diagnostic To Identify Patients With HER2-Low Metastatic Breast Cancer Eligible Ror ENHERTU

Moomoo 24/7Apr 10 02:50 ET

Novartis To Axe 680 Development Jobs Amid Global Reshuffle: Report

Novartis AG (NYSE:NVS) reportedly plans to slash up to 680 positions in its development organization, aiding in drug market launches.The Basel-based company announced that approximately 440 positions

BenzingaApr 9 12:33 ET

Syros Jumps on FDA Fast Track Tag for Leukemia Drug

Seeking AlphaApr 9 11:00 ET

ADC Therapeutics Gains After Data for Lymphoma Therapy

Seeking AlphaApr 4 13:11 ET

Roche Receives FDA Approval for the First Molecular Test to Screen for Malaria in Blood Donors

Yahoo FinanceMar 26 12:45 ET

Argenx Gains After Setback to Roche/Chugai Myasthenia Gravis Therapy

Seeking AlphaMar 21 07:00 ET

Lonza to Buy U.S. Biologics Site From Roche for $1.2B

Seeking AlphaMar 20 06:14 ET